Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ACR | P10323 | 1/20 | 0.50 |
| ▸ | SCD5 | Q86SK9 | 5/20 | 0.49 |
| ▸ | SCD | O00767 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CFTR | P13569 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30047064 | 1.00 | MAPT (0.63) | MAPTALDH1A1LMNAL3MBTL1ACR | |
| SCHEMBL13363886 | 0.85 | MAPT (0.54) | MAPTALDH1A1SCD5SCDKDM4E | |
| SCHEMBL28525855 | 0.84 | MAPT (0.54) | MAPTALDH1A1LMNAL3MBTL1ACR | |
| SCHEMBL9902002 | 0.83 | MAPT (0.52) | MAPTALDH1A1LMNAL3MBTL1ACR | |
| SCHEMBL31434685 | 0.81 | MAPT (0.48) | MAPTALDH1A1LMNAL3MBTL1ACR | |
| SCHEMBL21523592 | 0.81 | CDC7 (0.53) | MAPTALDH1A1L3MBTL1ACRSCD5 | |
| SCHEMBL22619899 | 0.81 | MAPT (0.60) | MAPTALDH1A1LMNAL3MBTL1ACR | |
| SCHEMBL768649 | 0.80 | ACR (0.63) | MAPTALDH1A1LMNAL3MBTL1ACR | |
| SCHEMBL19336773 | 0.80 | SCD5 (0.55) | MAPTALDH1A1SCD5SCDMEN1 | |
| SCHEMBL21523688 | 0.79 | MAPT (0.61) | MAPTALDH1A1L3MBTL1ACRSCD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12325702-B2 | ATF6 inhibitors and uses thereof | ALTOS LABS, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-25 | — | — | US | disclosed |
| US-20240124434-A1 | ATF6 INHIBITORS AND USES THEREOF | ALTOS LABS, INC. | 2024-04-18 | — | — | US | disclosed |
| EP-4329889-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022232333-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2022-11-03 | — | — | WO | disclosed |
| US-20210221803-A1 | ATF6 INHIBITORS AND USES THEREOF | ALTOS LABS, INC. | 2021-07-22 | — | — | US | disclosed |
| US-20210221803-A1 | ATF6 INHIBITORS AND USES THEREOF | ALTOS LABS, INC. | 2021-07-22 | — | — | US | disclosed |
| EP-3774782-A2 | ATF6 INHIBITORS AND USES THEREOF | Black Belt TX Ltd (GB) | 2021-02-17 | — | — | EP | disclosed |
| CN-112313224-A | ATF6 inhibitors and uses thereof | 黑带医疗有限责任公司 | 2021-02-02 | — | — | CN | disclosed |
| US-10829485-B2 | ATF6 inhibitors and uses thereof | BLACK BELT TX LTD (GB) | 2020-11-10 | — | — | US | disclosed |
| WO-2010085582-A1 | SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010085582-A1 | SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-29 | — | — | WO | disclosed |
| US-20090209533-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES, INC. | 2009-08-20 | — | — | US | disclosed |
| WO-2009094028-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | CV THERAPEUTICS, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| US-20090124672-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | AMYGDALA NEUROSCIENCES, INC. | 2009-05-14 | — | — | US | disclosed |
| WO-2009061924-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | CV THERAPEUTICS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| EP-2046769-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | CV THERAPEUTICS, INC. (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080207610-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080032995-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION | AMYGDALA NEUROSCIENCES, INC. | 2008-02-07 | — | — | US | disclosed |
| WO-2008014497-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | CV THERAPEUTICS, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124434-A1 | ATF6 INHIBITORS AND USES THEREOF | ATF4, XBP1, ATF1 | MAPT 264/4885ALDH1A1 4447/4885LMNA 2920/4885 |
| US-12325702-B2 | ATF6 inhibitors and uses thereof | ATF4, XBP1, ATF1 | MAPT 264/4885ALDH1A1 4447/4885LMNA 2920/4885 |
| US-20080207610-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | ALDH1A1, ADH1A, ALDH3A1 | MAPT 1815/4885ALDH1A1 1/4885LMNA 4747/4885 |
| US-10829485-B2 | ATF6 inhibitors and uses thereof | ATF4, XBP1, ATF1 | MAPT 264/4885ALDH1A1 4447/4885LMNA 2920/4885 |
| US-20090209533-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | ALDH1A1, ADH1A, ALDH3A1 | MAPT 1815/4885ALDH1A1 1/4885LMNA 4747/4885 |
| US-20210221803-A1 | ATF6 INHIBITORS AND USES THEREOF | ATF4, XBP1, ATF1 | MAPT 264/4885ALDH1A1 4447/4885LMNA 2920/4885 |
| US-20080032995-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION | ALDH1A1, ADH1A, ALDH3A1 | MAPT 1778/4885ALDH1A1 1/4885LMNA 4708/4885 |
| US-20090124672-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | ALDH2, ALDH1A2, ALDH1A1 | MAPT 2549/4885ALDH1A1 3/4885LMNA 3416/4885 |
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | MAPT 3067/4885ALDH1A1 283/4885LMNA 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.